Dark

VLON
Vallon Pharmaceuticals Inc
stock NASDAQ

Inactive

4/21/2023 3:59:30 PM EDT

0.3975USD-13.587%(-0.0625)1,237

Overview HistoricalMore

open chart

Market Cap

9.707B

Industry

Pharmaceutical Preparation Manufacturing

Last Split

2023-04-241for30reverse

VLON Stats

Avg. Vol. 10 Day

1,640

Avg. Vol. 30 Day

869

Market Cap

9,707,286,240

52 Week Low

184.86

52 Week High

1,953.00

SMA50

375.25

SMA200

317.93

1 Week

+10.50%

1 Month

-0.52%

3 Month

+39.13%

6 Month

+24.22%

1 Year

-82.38%

2 Year

-91.09%

5 Year

-94.68%

Jan 20, 2022

08:35AM EST Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top GlobeNewswire Inc

Jan 18, 2022

08:16AM EST Vallon Pharmaceuticals Presents New Data From Adult Stimulant Abuse Pattern Survey At APSARD 2022 Annual Conference Benzinga

08:05AM EST -Survey results reinforce existing literature that immediate-release (IR) amphetamines, such as Adderall,are the most commonlyabused preparation of prescription stimulants GlobeNewswire Inc

Jan 4, 2022

08:05AM EST Vallon Pharmaceuticals to Present at the H.C. Wainwright GlobeNewswire Inc

Dec 23, 2021

08:06AM EST UPDATE: Vallon Pharma Sees Topline Results From SEAL Study Q1'22 Benzinga

More News

Profile

Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company's lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.

.dark-mode .rT5t0b{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .rT5t0b{ color: #333333; background-color: white; border: 2px solid #333333; }VLONVallon Pharmaceuticals Incstock NASDAQ

VLON
Vallon Pharmaceuticals Inc
stock NASDAQ